{
    "clinical_study": {
        "@rank": "146414", 
        "arm_group": [
            {
                "arm_group_label": "Atopic dermatitis patients: Active", 
                "arm_group_type": "Active Comparator", 
                "description": "Atopic dermatitis patients: age 1-18 years old"
            }, 
            {
                "arm_group_label": "Atopic dermatitis patients: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Atopic dermatitis patients: age 1-18 years old"
            }
        ], 
        "brief_summary": {
            "textblock": "Background: Increase in skin colonization of Staphylococcus aureus (S. aureus) in atopic\n      dermatitis patients (AD) resulted from the reduction of cathelicidin production in these\n      patients plays the important role in pathogenesis of this disease. Recently in vivo study\n      has showed that vitamin D can stimulate cathelicidin production. Oral supplement of vitamin\n      D might be beneficial in atopic dermatitis.\n\n      Objective: To determine the effect of oral vitamin D supplement on clinical impact including\n      skin colonization of S. aureus in atopic dermatitis patients."
        }, 
        "brief_title": "Effect of Oral Vitamin D Supplement on Atopic Dermatitis; A Clinical Trial With Staphylococcus Aureus Colonization Determination", 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible criteria included patients with mild to moderate atopic dermatitis by SCORAD\n             (Scoring for Atopic Dermatitis) score criteria1,17,18, age between 1-18 years old.\n             All patients had been advised to take normal, dietary product and their activities.\n             They had been advised to discontinue at least 4 weeks of oral corticosteroid, at\n             least 2 weeks of topical corticosteroid or topical calcineurin inhibitor application\n             and at least 6 months of vitamin supplement prior to starting the protocol\n\n        Exclusion Criteria:\n\n          -  The exclusion criteria were to coexisting skin infection on top with AD lesions,\n             known case of primary or secondary immune-compromised host, hepatic or renal disease,\n             those taking vitamin D or nutraceutical supplementation, those continues taking with\n             antibiotics, corticosteroid, immunosuppressive agents, anti-epileptic drugs, thiazide\n             diuretics, proton-pump inhibitors, histamine 2-receptor antagonists at the time of\n             enrollment. Patients who used topical antiseptic or antibiotic products during study\n             period were also excluded. Patients who developed worsening of AD with flare-up of\n             clinical manifestation or SCORAD greater than 40, secondary infection on-top tested\n             lesions were excluded from data analysis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058186", 
            "org_study_id": "218/2555"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atopic dermatitis patients: Active", 
                "intervention_name": "oral vitamin D", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atopic dermatitis patients: Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Atopic dermatitis, vitamin D supplementation, cathelicidin, Staphylococcus aureus colonization, SCORAD score", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10110"
                }, 
                "name": "Skin Center, Srinakharinwirot University"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Khon Kaen University Ethics Committee for Human Research"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "SCORAD score", 
            "safety_issue": "Yes", 
            "time_frame": "May - August 2012 (3 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058186"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Srinakharinwirot University", 
            "investigator_full_name": "Montree Udompataikul", 
            "investigator_title": "Skin Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Srinakharinwirot University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Srinakharinwirot University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}